Clinical Report: Aurelio B. Castrellon, M.D., Joins The Eugene M. and Christine E. Lynn Cancer Institute

Overview

Aurelio B. Castrellon, M.D., a board-certified medical oncologist specializing in breast cancer, has joined the Eugene M. and Christine E. Lynn Cancer Institute.

Background

The integration of specialized oncologists into cancer care teams is essential for addressing complex diseases like breast cancer. Dr. Castrellon's expertise in breast oncology, particularly in targeted therapies and immunotherapy, aligns with current trends in personalized cancer treatment.

Data Highlights

No numerical or trial data available in the source material.

Key Findings

• Dr. Castrellon specializes in breast cancer and provides evidence-based care.
• He has over a decade of experience at Memorial Cancer Institute.
• Dr. Castrellon is a nationally recognized expert in breast medical oncology.
• He emphasizes patient-centered care and individualized treatment plans.
• Fluent in multiple languages, he enhances communication with diverse patient populations.

Clinical Implications

The addition of Dr. Castrellon to the Lynn Cancer Institute highlights the role of specialized oncologists in cancer care.

Conclusion

Dr. Castrellon will contribute to the multidisciplinary cancer care team at the Lynn Cancer Institute.

Related Resources & Content

1. Baptist Health South Florida, Source, Year -- Spencer Streit, D.O., Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Medical Oncologist and Hematologist
2. Baptist Health South Florida, Source, Year -- Kfir Ben-David, M.D., FACS, Joins The Eugene M. and Christine E. Lynn Cancer Institute as a Surgical Oncologist
3. Baptist Health South Florida, Source, Year -- Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies
4. The ASCO Post — ASCO Honors 2022 Special Awards Recipients
5. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
6. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update
7. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer | New England Journal of Medicine